Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.X-Chem, Ono to collaborate on multi-target drug discovery
Under the terms of the agreement X-Chem will apply its proprietary DEXTM libraries, which contain over 120 billion small molecules, toward the discovery of new drug leads against
Under the terms of the agreement X-Chem will apply its proprietary DEXTM libraries, which contain over 120 billion small molecules, toward the discovery of new drug leads against
As a newly established bioscience company in the immuno-oncology field and spin out from the French Atomic Energy Commission, H-Immune has developed a proprietary In Vitro Immunization (IVI)
NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that
Under the terms of the agreement, SalvaRx will invest US$1,000,000 for an initial holding of approximately 30% (including new shares issued on the conversion of a US$90,000 convertible
Oxford BioDynamics is one of six consortium partners to examine and address why immune-mediated inflammatory diseases (IMIDs) remit and relapse, with a particular focus on RA. The consortium,
HFrEF is also known as systolic heart failure (HF). Entresto is indicated to reduce the risk of cardiovascular (CV) death and hospitalization for HF in patients with chronic
Cell Medica will use the investment capital to continue to progress its three proprietary technology platforms for cell-based immunotherapy products. The Company’s lead oncology product, baltaleucel-T (CMD-003), is
Emflaza is the first treatment approved in the US for all Duchenne muscular dystrophy (DMD) patients five years and older, regardless of their genetic mutation. DMD is a rare
Molecular Psychiatry publishes their work based on a new approach on March 14. The human genome is made up of approximately 3 billion letters of DNA and at
The decision means that eligible adults with severe AD can access dupilumab before the drug is granted marketing authorisation in the UK. Allergy UK CEO Carla Jones said: